BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15259906)

  • 1. Antiretroviral treatment alters relationship between MCP-1 and neurometabolites in HIV patients.
    Chang L; Ernst T; St Hillaire C; Conant K
    Antivir Ther; 2004 Jun; 9(3):431-40. PubMed ID: 15259906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia.
    Sevigny JJ; Albert SM; McDermott MP; McArthur JC; Sacktor N; Conant K; Schifitto G; Selnes OA; Stern Y; McClernon DR; Palumbo D; Kieburtz K; Riggs G; Cohen B; Epstein LG; Marder K
    Neurology; 2004 Dec; 63(11):2084-90. PubMed ID: 15596754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART.
    Chang L; Ernst T; Witt MD; Ames N; Walot I; Jovicich J; DeSilva M; Trivedi N; Speck O; Miller EN
    Antivir Ther; 2003 Feb; 8(1):17-26. PubMed ID: 12713060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy.
    Marzocchetti A; Cingolani A; Giambenedetto SD; Ammassari A; Giancola ML; Cauda R; Antinori A; Luca AD
    J Neurovirol; 2005 Apr; 11(2):219-24. PubMed ID: 16036800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delayed central nervous system virus suppression during highly active antiretroviral therapy is associated with HIV encephalopathy, but not with viral drug resistance or poor central nervous system drug penetration.
    Eggers C; Hertogs K; Stürenburg HJ; van Lunzen J; Stellbrink HJ
    AIDS; 2003 Sep; 17(13):1897-906. PubMed ID: 12960822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment.
    Harezlak J; Buchthal S; Taylor M; Schifitto G; Zhong J; Daar E; Alger J; Singer E; Campbell T; Yiannoutsos C; Cohen R; Navia B;
    AIDS; 2011 Mar; 25(5):625-33. PubMed ID: 21297425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships among brain metabolites, cognitive function, and viral loads in antiretroviral-naïve HIV patients.
    Chang L; Ernst T; Witt MD; Ames N; Gaiefsky M; Miller E
    Neuroimage; 2002 Nov; 17(3):1638-48. PubMed ID: 12414302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma.
    Monteiro de Almeida S; Letendre S; Zimmerman J; Lazzaretto D; McCutchan A; Ellis R
    J Neuroimmunol; 2005 Dec; 169(1-2):144-52. PubMed ID: 16182380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing cerebrospinal fluid and plasma HIV-1 RNA detection rate in patients with and without opportunistic neurological disease during the HAART era.
    Christo PP; Greco DB; Aleixo AW; Livramento JA
    BMC Infect Dis; 2007 Dec; 7():147. PubMed ID: 18096083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible dementia in a patient with central nervous system escape of human immunodeficiency virus.
    Bogoch II; Davis BT; Venna N
    J Infect; 2011 Sep; 63(3):236-9. PubMed ID: 21658774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered neurometabolite development in HIV-infected children: correlation with neuropsychological tests.
    Keller MA; Venkatraman TN; Thomas A; Deveikis A; LoPresti C; Hayes J; Berman N; Walot I; Padilla S; Johnston-Jones J; Ernst T; Chang L
    Neurology; 2004 May; 62(10):1810-7. PubMed ID: 15159483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia.
    Chang L; Ernst T; Leonido-Yee M; Witt M; Speck O; Walot I; Miller EN
    Neurology; 1999 Sep; 53(4):782-9. PubMed ID: 10489041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy.
    Winston A; Duncombe C; Li PC; Gill JM; Kerr SJ; Puls RL; Taylor-Robinson SD; Emery S; Cooper DA;
    Neuroradiology; 2012 Dec; 54(12):1331-9. PubMed ID: 22772471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter in vivo proton-MRS study of HIV-associated dementia and its relationship to age.
    Chang L; Lee PL; Yiannoutsos CT; Ernst T; Marra CM; Richards T; Kolson D; Schifitto G; Jarvik JG; Miller EN; Lenkinski R; Gonzalez G; Navia BA;
    Neuroimage; 2004 Dec; 23(4):1336-47. PubMed ID: 15589098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF biomarkers of monocyte activation and chemotaxis correlate with magnetic resonance spectroscopy metabolites during chronic HIV disease.
    Anderson AM; Fennema-Notestine C; Umlauf A; Taylor MJ; Clifford DB; Marra CM; Collier AC; Gelman BB; McArthur JC; McCutchan JA; Simpson DM; Morgello S; Grant I; Letendre SL;
    J Neurovirol; 2015 Oct; 21(5):559-67. PubMed ID: 26069183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical factors related to brain structure in HIV: the CHARTER study.
    Jernigan TL; Archibald SL; Fennema-Notestine C; Taylor MJ; Theilmann RJ; Julaton MD; Notestine RJ; Wolfson T; Letendre SL; Ellis RJ; Heaton RK; Gamst AC; Franklin DR; Clifford DB; Collier AC; Gelman BB; Marra C; McArthur JC; McCutchan JA; Morgello S; Simpson DM; Grant I;
    J Neurovirol; 2011 Jun; 17(3):248-57. PubMed ID: 21544705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of CSF leukocytosis to compartmentalized changes in MCP-1/CCL2 in the CSF of HIV-infected patients undergoing interruption of antiretroviral therapy.
    Monteiro de Almeida S; Letendre S; Zimmerman J; Kolakowski S; Lazzaretto D; McCutchan JA; Ellis R
    J Neuroimmunol; 2006 Oct; 179(1-2):180-5. PubMed ID: 16901548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals.
    Letendre SL; Zheng JC; Kaul M; Yiannoutsos CT; Ellis RJ; Taylor MJ; Marquie-Beck J; Navia B;
    J Neurovirol; 2011 Feb; 17(1):63-9. PubMed ID: 21246320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Impact of highly active antiretroviral therapy on plasma MCP-1 and MSP in AIDS patients].
    Yao HP; Jin CZ; Zhang FJ; Feng L; Wei HS; Wu LJ; Gao GJ; Armin B; Norbert B; Wu NP
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2007 Mar; 36(2):174-8. PubMed ID: 17443907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
    Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
    Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.